DEA Reschedules Hydrocodone Combination Products

Move from schedule III to schedule II means tighter prescribing rules

The U.S. Drug Enforcement Administration (DEA) recently released its final rule to reschedule hydrocodone combination products (HCPs) from schedule III to schedule II of the Controlled Substances Act (CSA). The change goes into effect on Oct. 6, 2014.

The move by the DEA follows an October 2013 recommendation by the Food and Drug Administration (FDA) and comes more than a decade after the DEA first recommended reclassifying hydrocodone. The move is partially based on findings that abuse of HCPs has risen dramatically in recent years.

This content is only available to members of the AAOS.

Please log in using the link at the top right corner of this page to access your exclusive AAOS member content.

Not a member? Become a member!